<div id="readability-page-1"><p>Barclays analyst Etzer Darout maintained a Buy rating on Oruka Therapeutics today and set a price target of $160.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Darout is a 5-star analyst with an average return of <span>26.4%</span> and a 56.04% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Jazz Pharmaceuticals.</p> <p>Currently, the analyst consensus on Oruka Therapeutics is a Strong Buy with an average price target of $128.50.</p></div>

ORKA

<p>Barclays analyst Etzer Darout has maintained a Buy rating on Oruka Therapeutics (ORKA) with a price target of $160.00. Darout, a 5-star analyst with a 26.4% average return and 56.04% success rate, focuses on the Healthcare sector. The consensus on Oruka Therapeutics is a Strong Buy, with an average price target of $128.50.</p>

Tip Ranks

Oruka Therapeutics

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares US Pharma

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Barclays

Incyte

Legend Biotech

Jazz Pharma

Barclays Remains a Buy on Oruka Therapeutics (ORKA)